October 19, 2015 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the late-breaking sessions at its annual conference, VIVA 2015. Sixteen trial results, featuring the latest in vascular technology and devices, will be released for the first time Nov. 2-3 at the Wynn Las Vegas.
Presentations of the late-breaking trials (including the embargoed results) will be presented during the General Session and highlighted during press conferences.
Scheduled presentations cover numerous categories, including:
New Devices
- Autogenous Arteriovenous Fistula Creation for Hemodialysis Access: Preliminary Results of the NEAT Trial
- First-in-Man Study of the MobiusHD for the Treatment of Resistant Hypertension
- Results of the VISION (combined imaging/atherectomy) Trial
New Procedures
- Percutaneous Endovascular Bypass of Long SFA Occlusions: Interim Trial Results
Drug-eluting Stents and Drug Coated Balloons
- MAJESTIC: DES 12-Month Performance Overall and in Diabetic Patients
- Results from the IN.PACT Global Study
- Results from the IN.PACT SFA IDE Trial
- ILLUMENATE FIH: Two-year Results on the Stellarex DCB without Pre-dilatation
- The Lutonix Global DCB Registry in Complex Femoro-popliteal Lesions
- Zilver PTX Post-Market Surveillance Study in Japan: 24 Month Results
Aortic Aneurysm Repair
- Least Invasive Fast-track EVAR: Midterm Results of the Multicenter LIFE registry
- Endovascular Repair in Acute Type B Aortic Dissection: Two-year Results from the Valiant US-IDE Study
- Four-Year Results Evaluating the Safety and Effectiveness of the Ovation System
Economic & Clinical Impact
- DURABILITY Iliac & VISIBILITY Iliac Combined Clinical Trials
- The SAPPHIRE Worldwide Study, the largest CAS experience ever presented
- Economic Analysis of Endovascular Interventions to Treat Femoro-popliteal Artery Disease
For more information: www.vivaphysicians.org
November 12, 2025 
